When was Adimab founded?

Adimab was founded in 2007 and raised its 1st funding round within a year of its incorporation.

Where is Adimab located?

Adimab is headquartered in Lebanon, United States.

How many employees does Adimab have?

As of May 31, 2026, the latest employee count at Adimab is 136.

Is Adimab a funded company?

Adimab is a funded company, having raised a total of $35.4M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 20, 2007.

When was the latest funding round of Adimab?

Adimab's latest funding was a $***** Series F round on Apr 02, 2012, with participation from 0 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $2.19B in funding in 2026 to date.

Where does Adimab rank among its competitors?

Adimab ranks 2nd amongst 21 active competitors, of which 12 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Laigo Biotechnology, which secured $6.36M in Mar, 2026.

Who are the top competitors of Adimab?

Adimab's top competitors include Antiverse, BigHat and Chai Discovery. Among them, Laigo Biotechnology secured the most recent funding round in March, 2026.

Adimab - 2026 Company Profile, Team, Funding & Competitors

Adimab is a series F company based in Lebanon (United States), founded in 2007 by Errik Anderson, Karl Dane Wittrup and Tillman Gerngross. It operates as an Antibody discovery and optimization platform for autoimmune and infectious diseases. Adimab has raised $35.4M in funding from investors like Polaris Partners, SV Health Investors and Google Ventures. The company has 21 active competitors, including 12 funded and 2 that have exited. Its top competitors include companies like Antiverse, BigHat and Chai Discovery.

Company Details

Antibody discovery and optimization platform for autoimmune and infectious diseases. The company’s platform also delivers and optimizes diverse panels of therapeutically relevant antibodies that meet the most standards for affinity, epitope coverage, species cross-reactivity, and developability.

Website: adimab.com
Email ID: *****@adimab.com
Phone Number: +1 **********

Key Metrics

Founded Year

2007

Location

Lebanon, United States

Stage

Series F

Total Funding

$35.4M in 6 rounds

Latest Funding Round

Series F, Apr 02, 2012, $*****

Investors

Polaris Partners & 11 more

Ranked

2^nd among 21 active competitors

Employee Count

136 as on May 31, 2026

Investment & Acquisitions

Adagio

Similar Companies

Antiverse & 19 more

View Adimab's full profile

Adimab is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Adimab, Llc CIN: 80-0669559 , United States, Active	Dec 14, 2010	-	121 (As on Dec 31, 2021)	-

Adimab has raised a total funding of $35.4M over 6 rounds. Its first funding round was on Jul 20, 2007. Adimab has 12 institutional investors.

Here is the list of recent funding rounds of Adimab:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 02, 2012	9172123	Series F	7533315	9307874	3363641	9354714
Nov 29, 2010	3651790	Series E	1976459	3355471	8418370	5968852
Oct 06, 2009	2662189	Series D	9212643	8020998	Google Ventures	Orbimed & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Adimab's funding rounds and investors

The founders of Adimab are Errik Anderson, Karl Dane Wittrup and Tillman Gerngross.

Here are the details of Adimab's key team members:

Errik Anderson: Co-Founder of Adimab and founder of 7 other companies, including Freejacks, X4 Pharmaceuticals and Avitide. They serve on the board of 1 company.
Karl Dane Wittrup: Co-founder, Chair of the SAB of Adimab and founder of 6 other companies, including biodisplay, 76Bio and Immunitas Therapeutics.
Tillman Gerngross: Co-Founder of Adimab and founder of 1 other company.
Contact Info: 1 email address

View details of Adimab's Founder profiles and Board Members

Adimab's employee count trend

Adimab has 136 employees as of May 26. Here is Adimab's employee count trend over the years:

Uncover Adimab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adimab include Antiverse, BigHat and Chai Discovery. Here is the list of Top 10 competitors of Adimab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antiverse 2017, Cardiff (United Kingdom), Series A	Developer of computational platform for de novo design of antibody therapeutics	$20M	Kadmos Capital, Cambridge Angels & 34 others	68/100
2nd	Adimab 2007, Lebanon (United States), Series F	Antibody discovery and optimization platform for autoimmune and infectious diseases	$35.4M	Google Ventures, Premji Invest & 10 others	65/100
3rd	BigHat 2019, San Carlos (United States), Series B	Provider of antibody therapies developed by machine learning and synthetic biology	$148M	Andreessen Horowitz, S32 & 13 others	63/100
4th	Chai Discovery 2023, San Francisco (United States), Series B	Developer of artificial intelligence models for de novo molecular design	$230M	Menlo Ventures, Oak HC/FT & 18 others	63/100
5th	Oncimmune 2006, Cambridge (United States), Acquired	Immunodiagnostics company developing biomarker platforms for cancer and immune diseases	-	IPF Partners, Balderton Capital & 9 others	58/100
6th	AbSci 2011, Vancouver (United States), Public	Developer of AI based technology for the production of recombinant protein for therapeutic applications	$228M	Casdin Capital, Redmile Group & 22 others	57/100
7th	LabGenius Therapeutics 2012, London (United Kingdom), Series B	Developer of an automated platform for therapeutic antibody discovery	$69.5M	Atomico, Obvious Ventures & 15 others	55/100
8th	Laigo Biotechnology 2023, Utrecht (Netherlands), Seed	Developer of targeted protein degradation technology for therapeutic applications	$19.8M	Kurma Partners, Curie Capital & 8 others	47/100
9th	immunitoAI 2020, Bengaluru (India), Series A	Developer of AI-based platform for antibody discovery and therapeutics	$7.93M	C-CAMP, pi Ventures & 30 others	47/100
10th	Ordaos 2019, New York City (United States), Seed	Provider of an AI accelerator for biomedical research and drug discovery	$21.5M	VTC Ventures, Route 66 Ventures & 5 others	47/100